Celgene Corp.

( )
CELG PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.88%60.550.0%$910.02m
NVAXNovavax, Inc. -0.88%103.64102.0%$818.54m
AMGNAmgen, Inc. 0.72%254.971.3%$738.81m
REGNRegeneron Pharmaceuticals, Inc. 1.12%648.052.5%$695.49m
GILDGilead Sciences, Inc. 0.11%76.501.0%$677.27m
BIIBBiogen, Inc. 8.32%290.681.6%$621.59m
VRTXVertex Pharmaceuticals, Inc. -0.19%298.501.9%$521.99m
ILMNIllumina, Inc. 0.10%372.503.5%$297.56m
ALXNAlexion Pharmaceuticals, Inc. 0.00%112.462.0%$230.21m
BMRNBioMarin Pharmaceutical, Inc. 0.00%127.984.3%$212.65m
SGENSeattle Genetics, Inc. 0.00%176.146.1%$207.80m
SRNESorrento Therapeutics, Inc. 2.03%7.531.8%$199.14m
IMMUImmunomedics, Inc. 0.10%41.2011.0%$178.27m
SRPTSarepta Therapeutics, Inc. -0.24%163.5013.9%$166.84m
INCYIncyte Corp. -1.37%107.162.5%$163.73m

Company Profile

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.